Kyle Salyers

Kyle Salyers serves as the Chief Strategy Officer and Senior Vice President of Corporate Development at Health Catalyst since March 2013, while also holding various investment roles in companies such as par8o, Noxilizer, Nico Neuro and Spine, NeoChord, and others. Notably, Kyle co-founded CHV Capital and has been involved as an investor and board observer in multiple firms, including PerfectServe, Inc., Celleration, MedVentive, and MindFrame Inc. Education includes a Bachelor of Arts in Sociology and Economics from DePauw University, an MBA from the University of Notre Dame, and an Executive Education Certificate from Harvard Business School focusing on corporate governance.